TWST · Twist Bioscience Corp
Price
Snapshot
50 fields · last close| Market Cap | $10.99B |
| P/E | — |
| Float | 61.33M |
| Beta | 2.23 |
| Volatility | 55.6% |
| Exchange | NASDAQ |
| Sector | Biotechnology |
| Cap tier | Large cap |
| Macro sensitivity | Very High |
| Clavix score | 46 |
| Price | 161.95 |
| Change | −3.02% |
| Prev Close | 166.99 |
| Open | 158.04 |
| Day Low | 156.16 |
| Day High | 167.05 |
| Avg Vol | 2 |
| Avg $ Vol | $315.4M |
| 52W High | 167.05 |
| 52W Low | 23.30 |
| 52W Pos | 96.5% |
| From High | −3.05% |
| From Low | +595.06% |
| Max DD 1Y | −25.54% |
| Spread | 0.10% |
| Liquidity | Normal |
| SMA 20 | +16.35% |
| SMA 50 | +36.89% |
| SMA 200 | +132.41% |
| RSI (14) | 73.0 |
| Vol 30D | 92.1% |
| Vol 90D | 81.6% |
| 1Y Range | 23–167 |
| Daily bars | 516 |
| Perf Week | +31.26% |
| Perf Month | +17.28% |
| Perf Quarter | +90.71% |
| Perf Half Y | +272.75% |
| Perf Year | +519.17% |
| Perf YTD | +400.00% |
| Prev Day | −3.02% |
| Clavix | D+ |
| Debt / Eq | 0.00 |
| Curr Ratio | 3.64 |
| Int Cover | -801.0× |
| FCF Margin | — |
| Rev Growth | +23.2% |
| Profit | Unprofitable |
| Leverage | Low |
| Sector rank | 30 / 35 |
Clavix risk grade
regraded every trading dayTWST grades D+, 46 of 100. Steadiest on News Sentiment (59), most exposed on Price Stability (27, weak). 0 of the 4 weighted dimensions sit above the Biotechnology median. Ranks 30 of 35 in Biotechnology by Clavix score.
How rough the ride is
| TWST | Biotechnology median | |
|---|---|---|
| Betavs the overall market · lower is steadier | 2.23 | 0.51 |
| Volatilityannualized | 55.6% | 13.4% |
| Max drawdown, past yearworst peak-to-trough fall | −25.5% | — |
| Typical daily movemedian absolute daily change | 2.96% | — |
| Days beyond ±3%of the last 252 sessions | 12550% | — |
How its days are spread
Daily returns over the last 252 sessions in 1% bins. Moves beyond ±6% land in the end bins.
52-week range
The bar runs from the lowest to the highest close of the last 252 sessions; the marker is the latest close.
Drawdown from the 1-year peak
Percent below the running high over the last 12 months. Zero is a fresh high.
Market sensitivity
| TWST | Biotechnology median | |
|---|---|---|
| Beta to the markethow much it swings with the S&P 500 · lower is safer | 2.23 | 0.51 |
| Macro sensitivityrate, dollar and credit exposure bucket | Very High | Low56% of 36 |
Where it sits on the macro scale
Low means rates, the dollar and credit spreads barely move it. Very High means they drive a large share of its swings. The counts are how many Biotechnology names sit in each bucket.
Where it ranks in its sector
Rank by Clavix score within the sector. Right is the top of the sector.
Price performance
| TWST | |
|---|---|
| 1 week | +31.3% |
| 1 month | +17.3% |
| Year to date | +400.0% |
| 1 year | +519.2% |
Context for the rank, not itself a risk measure.
Recent coverage, scored
| TWST | |
|---|---|
| Articles scoredthe most recent scored coverage, up to 30 | 30since 6 Jul |
| Average score0 most bearish, 100 most bullish | 58 |
| Bullish · bearisharticles above 60 · below 40 | 18 · 9 |
| Directionarticles whose tone is improving vs worsening | 18 ↑ 9 ↓ |
Where the article scores land
Each bar is a 10-point band of article scores. Below 40 reads bearish, above 60 bullish.
Balance sheet, against the sector
The shaded band is the middle half of the 36 Biotechnology names Clavix covers; the tick is the sector median.
Growth
| TWST | |
|---|---|
| Revenue growthyear over year | +23.2% |
Financial Health is shown but does not count toward the grade. Why
0–100, higher is safer. The tick on each bar is the Biotechnology median. Click a dimension for the evidence behind it. Financial Health is shown but does not count toward the grade.
Recent news
most recent scored articles · the chip is the article’s score · click to openThe article teases that Twist Bioscience will both contribute to and draw from findings and earn revenue from participation, but the body is too short to identify a concrete development.
On September 16, 2026, Twist Bioscience announced an agreement with Lilly TuneLab under which Twist will run antibody characterization services to produce wet lab data that feeds Lilly's AI-driven drug discovery models. The stock rose 14%. No specific catalyst was identified.
VIRGINIA RETIREMENT SYSTEMS ET Al bought a new position in Twist Bioscience Corporation (NASDAQ:TWST - Free Report) during the second quarter, according to its most recent 13F filing with the SEC. The fund bought 15,938 shares of the company’s stock, valued at approximately $1,640,000. Several other hedge funds and other institutional investors also recently bought […]
BWS Financial began covering Twist Bioscience stock on Wednesday with a sell rating and a price target of $45.00. The article also notes that Evercore previously lowered its rating on the company, though details are cut off.
Bank of New York Mellon Corp opened a new position in Twist Bioscience in the second quarter, buying 191,698 shares worth $19.72 million, according to its SEC disclosure.
Nearest peers by size
Biotechnology| Ticker | Company | Grade | Mkt cap | P/E | Beta | |
|---|---|---|---|---|---|---|
| KRYS | Krystal Biotech Inc | B | $9.97B | 41.27 | 0.56 | Compare |
| MDGL | Madrigal Pharmaceuticals Inc | B | $12.28B | — | -1.09 | Compare |
| CYTK | Cytokinetics Inc | B | $9.56B | — | 0.40 | Compare |
| HALO | Halozyme Therapeutics Inc | B | $12.76B | 30.86 | 0.96 | Compare |
| ARWR | Arrowhead Pharmaceuticals Inc | C+ | $9.39B | — | 1.33 | Compare |
| BBIO | BridgeBio Pharma Inc | B | $13.02B | — | 0.98 | Compare |
| PTGX | Protagonist Therapeutics Inc | B | $9.25B | 111.61 | 1.18 | Compare |
| SYRE | Spyre Therapeutics Inc | — | $8.87B | — | 2.95 | Compare |
You just read one holding. Clavix reads the whole portfolio.
Every position you own, graded on the same five dimensions, with an alert when a grade moves. Three months free on iPhone.